This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pivotal Findings On Autoimmune Disease Shared At Lupus Research Institute "Forum For Discovery"

NEW YORK, Oct. 25, 2012 /PRNewswire/ -- The 12 th annual Lupus Research Institute (LRI) Scientific Conference "Forum for Discovery" brought together more than 60 of the country's top experts in the field to focus their talent on addressing the critical questions in the autoimmune disease lupus. LRI-funded investigators presented new findings on a broad range of topics including genetic factors that predispose certain individuals to lupus, how the lupus immune system turns against the body, and novel approaches to treat the disease.

A focal question of this year's two-day think tank was how to stem the destructive cycle of inflammation and organ damage in lupus. In lupus, inflammation is one of the most common causes of damage to vital organs such as the heart, brain, and kidneys. It results from the immune system attacking the body's own tissues as if there were an infection to fight off.  Two guest speakers, Drs. Eric Pamer at Memorial Sloan-Kettering Cancer Center and Charles Serhan at Harvard Medical School, shared pivotal advances in inflammation, stimulating an exchange on how their discoveries can influence lupus research.

LRI-funded investigators reported breakthrough results that have implications not only in lupus but also for the autoimmune diseases affecting 23.5 million Americans.  Findings include:

  • New insight into how the brain talks to the immune system to suppress inflammation in lupus was shared by Dr. Jane Salmon at Hospital for Special Surgery. Dr. Salmon's discovery may lead to a whole new approach to lupus treatment.
  • Dr. Carla Rothlin at Yale University reported that a blood protein (protein S) known to be low in lupus patients helps to turn off inflammation. This discovery could lead to new drugs that harness the power of protein S to treat lupus and other autoimmune diseases.
  • Dr. Anne Davidson, The Feinstein Institute, is using a new approach to find out why an existing rheumatoid arthritis drug anti-TNF can be protective in lupus kidney disease but also induces potentially harmful autoantibodies. Her findings suggest it may be possible to develop improved anti-TNF drugs that eliminate negative effects.
  • The "hot" new topic in lupus, epigenetics, was the focus of a presentation by Dr. Amr Sawalha at University of Michigan. Epigenetics tells us how the environment may activate a gene that triggers lupus; importantly this change can also be passed on to the next generation. Dr. Sawalha's work brings a long-sought missing piece to the puzzle of how lupus is inherited.

"The work presented at this Forum demonstrates the tremendous success of the LRI's strategic approach of funding the most novel scientific ideas in lupus," noted world-leading immunologist Dr. William Paul, LRI Scientific Advisory Board Chairman and National Academy of Sciences member. "The LRI continues to thrive on the union of scientists with the passion to pursue the most innovative scientific ideas with the patients and families who share that same passion to find new treatments and a cure for the disease."

Advancing new lupus treatments

Overcoming the many serious challenges impeding lupus drug development was the focus of an industry forum bringing together government, academia, and industry. One particularly well-received suggestion was to reduce the higher failure rate of drugs at late stage clinical trials by using biological tests (biomarkers) to show much earlier in development whether a drug is safe and has the expected biological effect.   

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,113.54 +61.81 0.36%
S&P 500 1,983.53 +9.90 0.50%
NASDAQ 4,456.0160 +31.3120 0.71%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs